Pipeline

SH-105

A treatment for Breast & Ovarian cancer

Disease state overview

SH-105 is well established for the treatment of cancer in adults, as evidenced by ongoing use across multiple indications:

  • Breast cancer​ (approximately 339,250 patients in the US diagnosed per year)1
  • Ovarian cancer (approximately 19,880 patients in the US diagnosed per year)1

Regulatory Status

The US Food and Drug Administration (‘FDA’) has approved Shorla Oncology’s New Drug Application (NDA) for TEPYLUTE, formerly SH-105. Bringing TEPYLUTE to market will benefit women suffering from breast and ovarian cancer and serve as a significant milestone on Shorla Oncology’s journey of bringing innovative oncology products to market. 

1 American Cancer Society. Cancer Facts & Figures, 2021.